BrainStorm Cell Therapeutics In
Brainstorm Cell Therapeutics develops autologous cellular therapies to treat neurodegenerative diseases. The company uses its NurOwn platform to induce stem cells to secrete neurotrophic factors and modulate disease processes. NurOwn has completed Phase III trials for ALS treatment and is also being developed for MS, Alzheimers, and other neurodegenerative diseases.
Overview
Strengths
- Creates economic value: ROIC of 71.3% against a cost of capital (WACC) of 11.5%, a spread of 59.8 percentage points.
- ROIC of 71.3% beats 91% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Shareholder dilution: the share count has grown by 65.2% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 7 of the last 7 years.
- Tight liquidity: current liabilities exceed current assets (current ratio 0.03).
- Small company (enterprise value $10 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data